Islet Management’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Islet Management’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-500,000	Closed	-$2.1M	–	48
2023 Q1	$2.1M	Buy	500,000 +20,000	+4%	+$104K	1.02%	20
2022 Q4	$2.88M	Buy	+480,000	New	+$2.62M	1.95%	16

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Islet Management's CTIC Position: Q1 2023 in Review

Islet Management sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q1 2023, closing a stake of 150,000 shares — an estimated $779K sold.

Islet Management first reported a position in CTIC in Q2 2022 and held it in 3 quarters. The position peaked at $5.97M in Q2 2022. 133 funds tracked by Wall St. Rank hold CTIC as of Q1 2023.

Islet Management reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q1 2023 after selling out during the quarter.
Islet Management sold 150,000 CTI BioPharma Corp. (DE) Common Stock shares in Q1 2023, an estimated $779K.
Islet Management first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2022 and held it in 3 quarters.
Islet Management's CTI BioPharma Corp. (DE) Common Stock position peaked at $5.97M in Q2 2022.
133 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q1 2023.

Based on Islet Management's 13F filing for Q1 2023, filed 15 May 2023.